Check the time stamp on this data. Updated AI-Generated Signals for Catalyst Pharmaceuticals Inc. (CPRX) available here: CPRX ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 11.63% ...

Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure ...

This was the stock's second consecutive day of losses.

Truist Financial analyst Joon Lee maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today. The company’s shares closed ...

View Catalyst Pharmaceuticals, Inc. (CPRX) current and estimated P/E ratio data provided by Seeking Alpha.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Shares of Catalyst Pharmaceuticals Inc. CPRX slipped 3.27% to $19.53 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP ...